Nightstar Therapeutics PLC (NITE):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Nightstar Therapeutics PLC (NITE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9415
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Nightstar Therapeutics PLC (Nightstar Therapeutics), formerly Nightstar Therapeutics Ltd, is a clinical-stage gene therapy company. The company focus on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases. Its lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia; and NSR-RPGR, a candidate that is in Phase 1/2 clinical trials for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease. The company also develops NSR-BEST1, a candidate that is in preclinical development stage for the treatment of best vitelliform macular dystrophy; and NSR-ABCA4, a candidate that is in preclinical development stage for the treatment of Stargardt disease. It develops retinal gene therapies for patients suffering from rare inherited retinal disease. Nightstar Therapeutics is headquartered in London, the UK.

Nightstar Therapeutics PLC (NITE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Nightstar Therapeutics PLC, Medical Devices Deals, 2012 to YTD 2018 9
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
NightstaRx Raises USD45 Million in Series C Financing 11
NightstaRx Raises USD35 Million in Series B Financing Round 12
Nightstar Raises Additional USD8.2 Million in Venture Financing Round 13
NightstaRx Raises US$19.8 Million In Venture Financing 14
Licensing Agreements 15
Nightstar Therapeutics Enters into Licensing Agreement with Oxford University Innovation 15
NightstaRx Enters into Licensing Agreement with Oxford University 16
NightstaRx Expands Licensing Agreement with Isis Innovation 17
NightstaRx Enters into Licensing Agreement with Oxford University Innovation 18
Equity Offering 19
Nightstar Therapeutics Raises USD86.3 Million in Public Offering of American Depository Shares 19
Nightstar Therapeutics Raises USD86.3 Million in IPO 21
Nightstar Therapeutics PLC – Key Competitors 23
Nightstar Therapeutics PLC – Key Employees 24
Nightstar Therapeutics PLC – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Aug 13, 2018: Nightstar Therapeutics reports second quarter 2018 financial results and business highlights 26
Jun 06, 2018: Nightstar Therapeutics Reports First Quarter 2018 Financial Results 28
Apr 03, 2018: Nightstar Therapeutics Reports 2017 Financial Results and Business Highlights 29
Corporate Communications 31
Sep 13, 2018: Nightstar Therapeutics names Paula Cobb as Board Director 31
Product News 32
03/19/2017: NightstaRx Commences first Phase I/II Gene Therapy Clinical Trial for Patients with X-Linked Retinitis Pigmentosa 32
Clinical Trials 33
Mar 05, 2018: Nightstar Therapeutics Announces Initiation of STAR Phase 3 Registrational Trial for NSR-REP1 in Choroideremia 33
Other Significant Developments 34
Oct 09, 2018: Gene therapy breakthrough in treating a rare form of blindness 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Nightstar Therapeutics PLC, Deals By Therapy Area, 2012 to YTD 2018 8
Nightstar Therapeutics PLC, Medical Devices Deals, 2012 to YTD 2018 9
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
NightstaRx Raises USD45 Million in Series C Financing 11
NightstaRx Raises USD35 Million in Series B Financing Round 12
Nightstar Raises Additional USD8.2 Million in Venture Financing Round 13
NightstaRx Raises US$19.8 Million In Venture Financing 14
Nightstar Therapeutics Enters into Licensing Agreement with Oxford University Innovation 15
NightstaRx Enters into Licensing Agreement with Oxford University 16
NightstaRx Expands Licensing Agreement with Isis Innovation 17
NightstaRx Enters into Licensing Agreement with Oxford University Innovation 18
Nightstar Therapeutics Raises USD86.3 Million in Public Offering of American Depository Shares 19
Nightstar Therapeutics Raises USD86.3 Million in IPO 21
Nightstar Therapeutics PLC, Key Competitors 23
Nightstar Therapeutics PLC, Key Employees 24
Nightstar Therapeutics PLC, Subsidiaries 25

List of Figures
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Nightstar Therapeutics PLC, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Nightstar Therapeutics PLC (NITE):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Gilead Sciences, Inc.:企業の戦略・SWOT・財務情報
    Gilead Sciences, Inc. - Strategy, SWOT and Corporate Finance Report Summary Gilead Sciences, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Pharnext SA (ALPHA):製薬・医療:M&Aディール及び事業提携情報
    Summary Pharnext SA (Pharnext), formerly Pharnext SAS is a biopharmaceutical company that develops novel therapies for severe neurodegenerative diseases. The company offers pleotherapy, a proprietary research and development platform based on network pharmacology that uses wide genomic data to ident …
  • Genetic Technologies Ltd (GTG):企業の財務・戦略的SWOT分析
    Genetic Technologies Ltd (GTG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Sun Life Financial Inc:企業のM&A・事業提携・投資動向
    Sun Life Financial Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sun Life Financial Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • BioMedomics Inc-医療機器分野:企業M&A・提携分析
    Summary BioMedomics Inc (BioMedomics) is a point-of-care diagnostics company that develops immunologically-based disease-specific tests and advanced highly sensitive quantitative platforms. The company provides technologies such as time-resolved lateral flow immunoassay and nanotube based POC platfo …
  • Humana Inc (HUM):企業の財務・戦略的SWOT分析
    Humana Inc (HUM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • CBIZ Inc (CBZ):企業の財務・戦略的SWOT分析
    Summary CBIZ Inc (CBIZ) is a provider of financial and advisory services. It offers accounting and tax; and insurance and human resource solutions. The company offers accounting and tax services such as audit and assurance, tax consulting and advisory services. Its insurance and human resource servi …
  • Ortho Kinematics Inc:医療機器:M&Aディール及び事業提携情報
    Summary Ortho Kinematics Inc (Ortho Kinematics) is a medical device company that provides diagnostic technology solutions. The company develops and provides spine imaging tests including VMA, and VMA-ALIGN. Its VMA is a vertebral motion analysis system used for testing the spine that produces X-ray …
  • Bioneer Corp (064550):製薬・医療:M&Aディール及び事業提携情報
    Summary Bioneer Corp (Bioneer) is a molecular diagnostic company that develops and produces molecular research and molecular diagnostic products and instruments. The company’s major molecular research products include DNA/RNA amplification pre mixes, DNA/RNA preparation system, oligo synthesis and r …
  • WPX Energy Inc (WPX):企業の財務・戦略的SWOT分析
    WPX Energy Inc (WPX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Eurofarma Laboratorios SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Eurofarma Laboratorios SA (Eurofarma), formerly Bill Farmaceutica is a pharmaceutical company that manufactures and markets prescription, generic and veterinary drugs. The company offers prescription products such as aerosol ointment, alprazolam, acebrophylline, altiva, ebastel, fluoruracila …
  • Sodra Skogsagarna ekonomisk forening:企業の戦略的SWOT分析
    Sodra Skogsagarna ekonomisk forening - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Kraton Polymers LLC:企業の戦略的SWOT分析
    Kraton Polymers LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • PT Dahana:企業の戦略・SWOT・財務情報
    PT Dahana - Strategy, SWOT and Corporate Finance Report Summary PT Dahana - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • CymaBay Therapeutics Inc (CBAY):企業の財務・戦略的SWOT分析
    CymaBay Therapeutics Inc (CBAY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Lebara Group:企業の戦略的SWOT分析
    Lebara Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Regeneron Pharmaceuticals, Inc.:企業の戦略・SWOT・財務情報
    Regeneron Pharmaceuticals, Inc. - Strategy, SWOT and Corporate Finance Report Summary Regeneron Pharmaceuticals, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Anthem Inc (ANTM):製薬・医療:M&Aディール及び事業提携情報
    Summary Anthem Inc (Anthem), formerly WellPoint Inc, is a health benefits company. It offers managed healthcare related products and administrative services. The company provides various specialty and insurance products and services including radiology benefit management, dental, life and disability …
  • Kazanorgsintez (KZOS):企業の財務・戦略的SWOT分析
    Kazanorgsintez (KZOS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • The AES Corporation:発電所・企業SWOT分析
    The AES Corporation – Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆